CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma

(University of Texas M. D. Anderson Cancer Center) According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Authors: Kienle DL, Stilgenbauer S Abstract Introduction: PI3K inhibition with idelalisib (at that time CAL-101) was at the forefront of the development of molecularly targeted therapies in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) and follicular lymphoma. However, after initial approval, subsequent trials identified specific immune-mediated and infectious toxicity that led to a reduced use and stopped the further development of this agent. PI3K inhibition as a treatment paradigm fell out of favor compared to other developments such as BTK or BCL2 inhibitors.Areas covered: This review prov...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
(Scripps Research Institute) Calibr, the drug discovery and development division of Scripps Research, today announced that the US Food and Drug Administration has given clearance to the Investigational New Drug (IND) application for Calibr's 'switchable' CAR-T cell therapy, which is being evaluated for the treatment of certain cancers, including relapsed/refractory B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Bruton ’s tyrosine kinase (BTK) plays a pivotal role in B-cell proliferation and survival of leukemic cells. Ibrutinib, a molecule targeting BTK, was approved by the United States Food and Drug Administration in 2013 for treatment of mantle cell lymphoma and has since been approved for treatment of sever al other hematologic malignancies, including chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia, and marginal zone lymphoma (MZL).1 Recently, ibrutinib plus venetoclax have been found to be effective as first-line treatment for high-risk and older patients with CLL.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Bruton ’s tyrosine kinase (BTK) plays a pivotal role in B-cell proliferation and survival of leukemic cells. Ibrutinib, a molecule targeting BTK, was approved by the U.S. Food and Drug Administration in 2013 for treatment of mantle cell lymphoma and has since been approved for treatment of several other hematologic malignancies, including chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia, and marginal zone lymphoma (MZL) (1). Recently, Ibrutinib plus venetoclax have been found to be effective as first line treatment for high risk and older patients with CLL (2).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Chimeric antigen receptor (CAR)-T cell therapy is a new and powerful class of cancer immunotherapy [1,2]. Clinical trials of CAR-T cell therapy targeting the B cell marker CD19 have shown promising results for the treatment of hematologic malignancies, including acute lymphoblastic leukemia (ALL) [3-7], chronic lymphocytic leukemia [8,9], and non-Hodgkin lymphoma (NHL) [10,11]. CAR-T cell therapy targeting B cell maturation antigen (BCMA) has also been demonstrated to be effective for treating multiple myeloma (MM) [12-15].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Chimeric antigen receptor (CAR)-T cell therapy is a new and powerful class of cancer immunotherapy [1,2]. Clinical trials of CAR-T cell therapy targeting the B-cell marker CD19 have shown promising results for the treatment of hematologic malignancies, including acute lymphoblastic leukemia (ALL) [3 –7], chronic lymphocytic leukemia (CLL) [8,9], and non-Hodgkin lymphoma (NHL) [10,11]. CAR-T cell therapy targeting B-cell maturation antigen (BCMA) has also been demonstrated to be effective for treating multiple myeloma (MM) [12–15].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
CONCLUSION: In a real-world setting, the QLQ-C30 summary score has a strong prognostic value for overall survival for a number of populations of patients with cancer above and beyond that provided by clinical and sociodemographic variables. The QLQ-C30 summary score appears to have more prognostic value than the global QoL, physical functioning, or any other scale within the QLQ-C30. IMPLICATIONS FOR PRACTICE: The finding that health-related quality of life provides distinct prognostic information beyond known sociodemographic and clinical measures, not only around cancer diagnosis (baseline) but also at follow-up, ha...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Targeted therapy is revolutionizing the treatment of cancers, but resistance evolves against these therapies and derogates their success. The phosphatidylinositol 3-kinase delta (PI3K-) inhibitor idelalisib has been approved for treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma, but the mechanisms conferring resistance in a subset of patients are unknown. Here, we modeled resistance to PI3K- inhibitor in vivo using a serial tumor transfer and treatment scheme in mice. Whole-exome sequencing did not identify any recurrent mutation explaining resistance to PI3K- inhibitor. In the murine model, resistan...
Source: Blood - Category: Hematology Authors: Tags: Lymphoid Neoplasia Source Type: research
The objective is, therefore, to examine the relation between co-morbid CVD at cancer diagnosis and HRQoL among cancer survivors diagnosed with colorectal, thyroid, prostate, endometrium, ovarian cancer, melanoma, (non-)Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), or multiple myeloma (MM) in an exploratory population-based cross-sectional study. Material and methods: Analyses were performed on combined data sets from the PROFILES and Netherlands Cancer Registry (NCR). Data on co-morbid CVD at cancer diagnosis was extracted from the NCR. HRQoL was measured via PROFILES at a median of 4.6 years after cancer di...
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
354Background: Each year more than 90,000 cases of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) are expected in the US. The standard of care includes immuno-chemotherapy with alkylating agents in combination with an anti-CD20 monoclonal antibody, in addition to targeted therapies such as Bruton’s tyrosine kinase inhibitors. While immuno-chemotherapy regimens are initially effective in inducing responses, most patients inevitably relapse and the same therapies show decreasing efficacy with repeated administration. In recent years, CD37 has emerged as a new therapeutic target for B-cell malignancie...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Oncology, Basic and Translational (Basic Science) III Source Type: research
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Lymphoma | Non-Hodgkin's Lymphoma | Texas University | Toxicology